Study extension of JR-141 for long-term Hunter syndrome safety
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This is a follow-up study for people who already took JR-141 in an earlier trial for Hunter syndrome (MPS II). It checks how well the treatment works over the long term and monitors long-term safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously joined the parent JR-141 study (JR-141-GS31) and finished the required early check-ins (Week 105 for Cohort A or Week 53 for Cohort B).
- Your study doctor (principal investigator) feels there were no major safety concerns with your previous JR-141 treatment.
- You (or your legal representative/guardian if needed) can sign the consent form, and you’ll try to provide “assent” if able.
- If you can have children, you must use highly effective birth control during the study and for a short time after the last dose.
- You must NOT have switched from JR-141 to another medicine called idursulfase during the parent study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with MPS II (Hunter syndrome) who have already completed a previous Denali study. It will test a drug called tividenofusp alfa (DNL310) over a longer period to see how safe it is and how well it works.
This study follows people with MPS, a rare genetic condition, to learn more about the disease over time. If you have a confirmed MPS diagnosis, you may be able to join.
This early-stage trial tests JR-446, a new treatment for MPS IIIB, a rare genetic disorder that affects the brain and body. The treatment is delivered directly into the fluid around the spinal cord and aims to slow or improve symptoms in young children.
This study follows people who previously received a gene-modified Treg (regulatory T cell) therapy from Sonoma Biotherapeutics. It checks for long-term safety and does not involve any new treatment.
This study follows participants who previously received the RGX-111 treatment to monitor their health over time. It helps researchers understand the long-term effects and safety of the therapy.
This study tests a new gene therapy called JWK008 for adults with MPS type I. The goal is to see if it is safe and can help improve symptoms. You may be able to join if you are 18 or older and have not had serious side effects from enzyme replacement therapy.
Hear when a new Mucopolysaccharidosis II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.